KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Accumulated Expenses (2018 - 2019)

Historic Accumulated Expenses for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Q4 2019 value amounting to $36.0 million.

  • Amneal Pharmaceuticals' Accumulated Expenses fell 5327.64% to $36.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $36.0 million, marking a year-over-year decrease of 5327.64%. This contributed to the annual value of $36.0 million for FY2019, which is 5327.64% down from last year.
  • Amneal Pharmaceuticals' Accumulated Expenses amounted to $36.0 million in Q4 2019, which was down 5327.64% from $77.1 million recorded in Q4 2018.
  • In the past 5 years, Amneal Pharmaceuticals' Accumulated Expenses ranged from a high of $77.1 million in Q4 2018 and a low of $36.0 million during Q4 2019